Catalyst Event
Sino Biopharmaceutical Ltd (1177) · Other
From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)
5/27/2026, 12:00:00 AM
The company announced positive Phase I clinical data for its liver-targeted THR-β agonist, Kylo-0603, for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) at the EASL 2026 Congress on 2026-05-27. This early-stage data is estimated to have a low market impact of approximately 1-2%.
Korean Translation
2026-05-27 유럽간학회(EASL)에서 대사기능장애 관련 지방간질환(MAFLD) 치료를 위한 간표적 THR-β 작용제 Kylo-0603의 긍정적인 1상 임상 데이터를 발표함. 초기 단계 데이터로 약 1-2%의 시장 영향이 예상됨.
Related Recent Events
Eli Lilly and Co (LLY) · Earnings Release
Q2 2026 earnings release and conference call. Medium importance is estimated as earnings releases typically cause >5% price volatility scheduled.
8/5/2026, 12:00:00 AM
Boston Scientific Corp (BSX) · Earnings Release
The Q2 2026 earnings release scheduled for 2026-07-29, for which high importance is estimated due to typical market volatility surrounding quarterly results, is expected.
7/29/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Q2 2026 earnings release is scheduled for July 16, 2026; a price impact of at least 5% is estimated based on historical volatility, scheduled.
7/16/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Final dividend of HKD 0.20 per share ex-dividend on July 3, 2026; standard corporate action with minor price adjustment scheduled.
7/3/2026, 12:00:00 AM
CSPC Pharmaceutical Group Ltd (1093) · Other
Ex-dividend date for the 2025 final dividend of HK$0.15 per share, which was announced on March 25, 2026. The payment date is July 15, 2026.
6/24/2026, 12:00:00 AM
Sonova Holding AG (SOON) · Other
Ex-dividend date (2026-06-19) for a proposed record-high annual dividend of CHF 4.70 per share; impact estimated at ~2% as dividend is record-high, scheduled.
6/19/2026, 12:00:00 AM